Physician profile
Sita Devulapalli
NPI 1578558904
$1,384.84
in general payments reported to CMS, 2019-2025
20 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $102 · 2021: $302 · 2022: $365 · 2023: $157 · 2024: $176 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.02 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $189.96 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $107.62 | 2022-2025 | |
| Pfizer INC. | $83.97 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $77.61 | 2020-2021 | |
| Novo Nordisk INC | $73.40 | 2021-2023 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $59.30 | 2020-2025 | Zoryve |
| Amgen INC. | $50.33 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.85 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.91 | 2020-2021 | |
| Allergan, INC. | $33.83 | 2020 | |
| Abbvie INC. | $32.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.30 | 2021-2024 | |
| Nevro Corp. | $23.96 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.98 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.29 | 2021 | |
| Glaxosmithkline, LLC. | $14.81 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $14.43 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sita Devulapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.